Two global markets — and the UK’s rising role
Lawrence Purkiss described the international cannabis market as split into two spheres: the US and the rest of the world.
The UK is now the fourth-largest medical cannabis market globally, having surpassed Israel and approaching parity with Canada.
Prescribed items have increased fivefold between January 2022 and May 2024. Growth is now tracking closely with Germany, both in speed and scale.
Private market growth, but outside the NHS
The UK market is entirely private, with no NHS reimbursement, placing the financial burden squarely on patients.
Clinics must focus on specific indications, and prescribing doctors must be on the specialist register. This creates a highly regulated but narrow pool of practitioners.
Telehealth has been critical, allowing a small number of doctors to serve a geographically dispersed patient base.
Unmatched product diversity, competitive pricing
Alex Khourdaji reported that the UK leads Europe in product diversity, with over 400 available SKUs — mostly flower, but also extracts, vapes, and edibles.
Average flower pricing stands at €8.30/g, slightly above Germany, with significant variance.
Portugal supplies lower-cost products; Australia and Canada provide high-THC premium products, often marketed on terpene profile and perceived quality.
Despite a relatively small patient base (~60,000–75,000 patients), meaning there is growing competition.
Persistent structural barriers
Stigma and restrictive prescribing rules limit the number of authorised doctors (approx. 174).
Bureaucratic import requirements, especially shipment-by-shipment licensing, drive up costs and burden healthcare providers.
Marketing restrictions suppress both patient awareness and professional engagement, making patient acquisition challenging.
Global comparisons and cautionary tales
While Germany garners most attention, the UK is catching up quickly in growth and accessibility, even without NHS integration.
Lessons from Australia, Germany, and Poland warn against rapid telehealth expansion without regulatory safeguards, which can trigger public and political backlash.
Measured growth and cautious optimism
Beau Whitney (Whitney Economics) highlighted the mismatch between public health ambition and available data, calling it ironic that governments cite education gaps, yet create the policies that prevent it.
Growth is expected to continue steadily, with the UK’s controlled model possibly protecting its long-term legitimacy.
Small-scale reforms like simplifying import rules and expanding prescriber education are politically feasible and could significantly enhance access.
However, mainstream policy reform remains unlikely in the near term. For now, the emphasis must be on evidence gathering, system refinement, and preserving credibility.
Continue at: https://businessofcannabis.com/cannabis-europa-2025-key-insights-day-2/
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
